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Background. Improving cytomegalovirus (CMV) immune-risk stratification in kidney transplantation is highly needed to es-
tablish guided preventive strategies.
Methods. This prospective, interventional, multicenter clinical trial assessed the value of monitoring pretransplant CMV-specific 
cell-mediated immunity (CMI) using an interferon-γ release assay to predict CMV infection in kidney transplantation. One hundred 
sixty donor/recipient CMV-seropositive (D+/R+) patients, stratified by their baseline CMV (immediate-early protein 1)–specific 
CMI risk, were randomized to receive either preemptive or 3-month antiviral prophylaxis. Also, 15-day posttransplant CMI risk 
stratification and CMI specific to the 65 kDa phosphoprotein (pp65) CMV antigen were investigated. Immunosuppression consisted 
of basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids in 80% of patients, whereas 20% received thymoglobulin in-
duction therapy. 
Results. Patients at high risk for CMV based on pretransplant CMI developed significantly higher CMV infection rates than 
those deemed to be at low risk with both preemptive (73.3% vs 44.4%; odds ratio [OR], 3.44 [95% confidence interval {CI}, 1.30–
9.08]) and prophylaxis (33.3% vs 4.1%; OR, 11.75 [95% CI, 2.31–59.71]) approaches. The predictive capacity for CMV-specific CMI 
was only found in basiliximab-treated patients for both preemptive and prophylaxis therapy. Fifteen-day CMI risk stratification 
better predicted CMV infection (81.3% vs 9.1%; OR, 43.33 [95% CI, 7.89–237.96]).
Conclusions. Pretransplant CMV-specific CMI identifies D+/R+ kidney recipients at high risk of developing CMV infection if 
not receiving T-cell–depleting antibodies. Monitoring CMV-specific CMI soon after transplantation further defines the CMV infec-
tion prediction risk. Monitoring CMV-specific CMI may guide decision making regarding the type of CMV preventive strategy in 
kidney transplantation.
clinical Trials Registration. NCT02550639.
Keywords.  cytomegalovirus; kidney transplantation; immune monitoring; cell-mediated immunity.
Cytomegalovirus (CMV) infection still remains one of the most 
common opportunistic infections occurring after transplanta-
tion [1], negatively challenging both patient and allograft sur-
vival [2, 3]. Despite the significant improvement made in the 
last decades refining the transplant risk assessment of CMV 
infection, fundamentally based on the donor (D)/recipient 
(R)–pair CMV (immunoglobulin G [IgG]) serostatus and the 
implementation of preventive strategies such as a systematic 
monitoring of viral replication in peripheral blood (preemptive) 
or using universal antiviral therapy (prophylaxis), an important 
number of patients will unpredictably develop CMV infec-
tion. An important body of evidence has shown the key role of 
CMV-specific cell-mediated immunity (CMI) controlling and 
abrogating CMV viral replication [4–7], thus suggesting that its 
functional assessment could help identifying at-risk patients of 
developing CMV infection beyond CMV serostatus. A number 
of sensitive immune assays measuring CMV-specific CMI have 
been developed in the last years to interrogate the cellular im-
mune risk of transplant patients to develop CMV infection [8]. 
Notably, though serologically positive recipients (R+) are con-
sidered to be protected against CMV, a significant number of 
patients may display weak or even absence of CMV-specific 
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CMV antigen, and have been shown to be at higher risk of CMV 
infection [9–11].
To validate these previous data, we designed the first pro-
spective, multicenter, interventional clinical trial in which D+/
R+ kidney transplant patients were stratified according to their 
pretransplant CMV (IE-1)–specific CMI risk by detecting in-
dividual interferon gamma (IFN-γ)–producing cells with a 
peptide-based enzyme-linked immunosorbent spot (ELISPOT) 
assay (T-SPOT.CMV), and subsequently randomized to receive 
either preemptive or 3-month antiviral prophylactic therapy. 
The main objective of this trial was to demonstrate whether 
pretransplant assessment of CMV (IE-1)–specific CMI would 
identify transplant patients at risk of developing CMV infec-
tion treated according to the 2 main preventive CMV strategies. 
Also, 15-day posttransplant CMV-specific CMI and the value 
of monitoring CMI against the 65 kDa phosphoprotein (pp65) 
CMV antigen were investigated.
METHODS
Study Design
We carried out a 12-month prospective, multicenter, observational 
study with an embedded randomized intervention according to 
antiviral preventive strategy, either preemptive or prophylaxis 
therapy, in CMV (IgG)–seropositive kidney transplant recipients 
(R+) of a seropositive kidney donor (D+) stratified according to 
their pretransplant CMV (IE-1)–specific CMI risk (Figure  1). 
The study was double-blinded with regard to the CMV-specific 
CMI and open-labeled regarding the type of preventive therapy. 
According to pretransplant CMI specific to the IE-1 CMV an-
tigen, patients were allocated in 2 groups, group A (low risk) and 
group B (high risk), and subsequently randomized in a 1:1 ratio to 
receive either 3-month antiviral prophylaxis (subgroups A1 and 
B1) or preemptive therapy (subgroups A2 and B2). Additional 
information about patient eligibility criteria, randomization, and 
masking procedures is provided in the Supplementary Methods. 
The study was conducted in compliance with the provisions of 
the Declaration of Helsinki and Good Clinical Practice guidelines 
and was approved by all respective institutional review boards 
(AC148/13). All patients provided written informed consent and 
could withdraw from the study at any time.
Main Endpoints of the Study
The primary endpoint was to evaluate the incidence of CMV 
infection in patients following preemptive therapy with a 
pretransplant high-risk CMV (IE-1)–specific CMI (group B2) 
as compared to those with low-risk CMV (IE-1)–specific CMI 
(group A2).
As secondary endpoints, the rates of CMV infection requiring 
antiviral treatment, CMV disease, and late-onset CMV infec-
tion after prophylaxis withdrawal; the impact of CMV-specific 
CMI according to the type of induction therapy; the influence 
of CMI against the pp65 CMV antigen; and the prediction-risk 
accuracy of CMV-specific CMI at 15 days posttransplantation 
were assessed in this study.
Clinical Definitions of CMV Infection
The definition of CMV infection and disease was based on the 
criteria recommended by the CMV Drug Development Forum 
[12]. CMV infection was defined as the detection of CMV DNA 
replication in whole blood or plasma. CMV disease was defined 
as evidence of CMV DNA replication with compatible symp-
toms, including both viral syndrome and invasive tissue disease. 
CMV infection requiring antiviral treatment was defined in 
this study as the presence of CMV disease or CMV DNA copies 
>4000 IU/mL in plasma or 10 000 IU/mL in whole blood. These 
cutoffs were agreed among all investigators and considered as 
clinically meaningful to initiate antiviral therapy in absence of 
any symptoms.
CMV Preventive Strategies, CMV Serology, and Microbiological Studies
Detailed information about the type of CMV preventive strat-
egies used, CMV serology, and microbiological studies is pro-
vided in the Supplementary Methods.
Immunosuppression
Chronic immunosuppression was homogeneous and based on 
induction therapy with basiliximab in 80% of patients, whereas 
20% received rabbit antithymocyte globulin (rATG) and were 
stratified to be equally allocated among groups. Maintenance 
immunosuppression was based on tacrolimus, mycophenolate 
mofetil, and prednisone (additional information is described in 
the Supplementary Methods).
Assessment of CMV-Specific Cell-mediated Immunity
The T-SPOT.CMV test (Oxford Immunotec Ltd, Oxford, United 
Kingdom), was used to assess the CMI against 2 major immuno-
genic CMV antigens (IE-1 and pp65) using overlapping peptide 
pools covering the whole antigen length at baseline (n = 160) 
and at 2 weeks (n  =  137) posttransplantation. In accordance 
with previous works [9, 10], only pretransplant T-SPOT.CMV 
response against the IE-1 antigen was used to stratify patients 
into the 2 different risk groups (cutoff of 20 IFN-γ spots/3 × 105 
peripheral blood mononuclear cells [PBMCs]). Specific infor-
mation about the T-SPOT.CMV methodology is provided in 
the Supplementary Methods.
Main conceptual definitions of CMV monitoring assays are 
depicted in the Supplementary Methods.
Sample Size and Statistical Analysis
For the primary analysis and according to previous reports 
[9, 10, 13, 14], assuming a 10% rate of infection in the low-
risk group (A2) and a 35% rate in the high-risk group (B2) 
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a significant difference between the 2 groups at the 5% signif-
icance level and with 80% power would require 52 subjects in 
the low-risk group and 28 in the high-risk group. This is based 
further on a prevalence of high-risk CMV (IE-1) CMI at base-
line among D+/R+ patients and a 83% sensitivity and 65% spec-
ificity of the CMV (IE-1)–specific ELISPOT test and a 10% 
withdrawal rate. A total of 160 subjects were therefore planned 
for recruitment.
All analyses, unless otherwise specified, were performed on 
an intention-to-treat basis, and statistical significance was as-
sessed at the 5% level. Receiver operating characteristic (ROC) 
curve analysis was done to evaluate the optimum cutoffs 
predicting CMV infection.
For the primary efficacy analysis (high-risk vs low-risk inci-
dence of CMV infection on preemptive therapy), the 2 groups 
were compared using a 1-sided χ 2 test. The odds ratio (OR) for 
infection was also calculated and presented with the associated 
95% confidence interval (CI). The same analysis was performed 
for other comparisons of overall risk. The risk of CMV infec-
tion over the study period was analyzed using Cox proportional 
hazards model, and Kaplan-Meier curves of the infection rate 
over time were produced. The mean time to infection with the 
associated error was reported, and the hazard ratio calculated 
with the associated 95% CI. Analyses were performed using 
SPSS version 23 software, and graphs were generated using 
GraphPad Prism version 6.0 software (GraphPad Software, San 
Diego, California).
RESULTS
Study Patients and Main Clinical Outcomes
The study groups were comparable regarding main base-
line demographic, clinical, and immunological characteristics 
(Table 1). The incidence of CMV infection and disease during 
the 12-month duration of the study was 57 of 160 (35.6%) and 9 
of 160 (5.6%), respectively. Four of 9 (44.4%) developed a CMV 
flulike syndrome, 4 of 9 (44.4%) enteritis, and 1 of 8 (12.5%) 
Figure 1. Flowchart of the study. Between 10 June 2014 and 10 September 2017, 219 patients from 5 different transplant centers were screened and 160 underwent ran-
domization. Of the total 219 patients, 59 failed screening; among them, 8 were excluded because of poor blood sample conditions and 2 because of baseline cytomegalovirus 
(CMV) immunoglobulin G–seronegative status, and 49 patients with low-risk CMV (immediate-early protein 1 [IE-1])–specific cell-mediated immunity (CMI) were excluded 
as this study arm (group A) was already completed. The prevalence of high-risk and low-risk CMV (IE-1) CMI among the recipient-seropositive (R+) study population in whom 
the pretransplant T-SPOT.CMV assay was performed was 27.3% (57/209) and 72.7% (152/209), respectively. Twenty-three (14.3%) patients discontinued the study: 10 of 103 
(9.7%) in the low-risk group (1 [0.9%] in the prophylaxis A1 arm and 9 [8.7%] in the preemptive A2 strategy), and 13 of 57 (22.8%) within the high-risk CMI group (9 [15.8%] 
in the prophylaxis B1 arm and 4 [7%] in the preemptive B2 therapy). Thus, a total of 137 (85.7%) patients completed 12-month follow-up. Abbreviation: CMV, cytomegalo-
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pneumonitis. CMV infection rates according to each antiviral 
preventive therapy are depicted in Supplementary Table 1. No 
major differences were observed between patients developing 
CMV infection or disease and those who did not, but patients 
developing CMV infection displayed higher human leukocyte 
antigen (HLA) class I and II antigen mismatches. Mean time to 
CMV infection, mean time to disease, and mean time of infection 
duration in preemptively treated patients were 1.56 ± 0.8 months, 
2.84 ± 1.7 months, and 0.84 ± 0.63 months, respectively, com-
pared with 3.87  ±  1.76  months, 3.5  months, and 0.87  ±  0.74 
months in patients receiving prophylaxis. Thirty-three (20.6%) 
patients required antiviral therapy initiation due to either CMV 
disease (9/33 [27.3%]) or as prespecified per protocol due to 
CMV DNA >4000 IU/mL in plasma (20/33 [60.6%]) or >10 000 
IU/mL in whole blood (4/33 [12.1%]).
Primary Endpoint of the Study
Pretransplant high-risk CMV-specific CMI patients on pre-
emptive therapy (group B2) showed significantly higher inci-
dence of CMV infection than low-risk CMI patients (group A2) 
(22/30 [73.3%] vs 24/54 [44.4%], respectively; OR,  3.44 [95% 
CI, 1.30–9.08]). Likewise, the incidences of CMV infection re-
quiring treatment and CMV disease were significantly higher 
within high-risk than low-risk CMI patients (16/30 [53.3%] vs 
10/54 [18.5%], respectively, OR, 5.03 [95% CI, 1.86–13.57] for 
CMV infection requiring treatment; and 6/30 [20%] vs 2/54 
[3.7%], respectively, OR,  6.50 [95% CI, 1.22–34.59] for CMV 
disease) (Table 2). As illustrated in Figure 2, the cumulative in-
cidences of CMV infection, CMV infection requiring treatment 
and CMV disease were significantly higher among high-risk 
CMI than in low-risk CMI patients.
Figure 2. Cytomegalovirus (CMV) infection rates between pretransplant high-risk and low-risk CMV (immediate-early protein 1)–specific cell-mediated immunity in all pa-
tients following preemptive therapy. Kaplan-Meier curves for CMV infection-free survival analysis (A), CMV infection requiring antiviral treatment-free survival analysis (B), 
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Secondary Endpoints of the Study
Effect of Pretransplant CMV (IE-1)–Specific CMI According to 
Different Induction Therapies in Patients Following Preemptive 
Therapy
Among patients receiving basiliximab induction therapy, 
high-risk CMI patients displayed significantly higher inci-
dence of CMV infection, CMV infection requiring treatment, 
and CMV disease than low-risk CMI recipients (Table  2). 
Likewise, the cumulative incidences of CMV infection, CMV 
infection requiring treatment, and CMV disease were signifi-
cantly higher among high-risk CMI than low-risk CMI patients 
(Supplementary Figure 1).
Conversely, in rATG-treated patients, no association was ob-
served between pretransplant CMI and incidence of CMV in-
fection or disease.
Similar data were observed when patients on protocol were 
analyzed (Supplementary Table 2).
Impact of Pretransplant CMV (IE-1)–Specific CMI in Patients 
Receiving Antiviral Prophylaxis Therapy
Regardless of induction therapy used, pretransplant high-risk 
CMV-specific CMI patients on prophylaxis showed signifi-
cantly higher incidence of late-onset CMV infection compared 
with low-risk CMI patients (9/33 [33.3%] vs 2/49 [4.1%], re-
spectively, OR, 11.75 [95% CI, 2.31–59.71] for CMV infection; 
and 5/27 [18.5%] vs 2/49 [4.1%], respectively, OR, 5.34 [95% CI, 
.96–29.71] for CMV infection requiring treatment) (Table  2). 
The very low incidence of late-onset CMV disease (only 1 event 
among the high-risk group) precluded performing any analysis 
(Figure 3). Four high-risk CMI patients randomized to prophy-
laxis treatment (B1) followed a preemptive strategy and were 
dropped from the study. Three of these 4 patients developed 
CMV infection during the first 3 months posttransplantation.
When only basiliximab-treated patients were analyzed, high-
risk CMI patients displayed higher rates of late-onset CMV 
infection and infection requiring treatment compared with 
low-risk CMI recipients (Supplementary Figure 2 and Table 2).
The very low incidence of late-onset CMV infection among 
rATG-treated patients did not allow further analysis in 
this group.
Similar results were observed when patients on protocol were 
evaluated (Supplementary Table 2).
Pretransplant CMV-Specific T-Cell Frequencies Predicting CMV 
Infection
Subsequently, we investigated the most accurate CMV-specific 
CMI threshold against both IE-1 and pp65 CMV antigens 
predicting CMV infection. Patients developing CMV infec-
tion and disease displayed significantly lower IE-1 but not pp65 
IFN-γ T-cell frequencies than patients who did not, whereas pa-
tients developing CMV infection requiring antiviral treatment 
showed lower T-cell responses against both IE-1 and pp65 CMV 
antigens than those who did not (Supplementary Figure 3A–C). 
Stronger differences were observed when only basiliximab-
treated patients were evaluated (Supplementary Figure 3D–F). 
Conversely, no differences were found among rATG-treated pa-
tients (Supplementary Figure 3G and 3H).
Also, no significant differences were observed regarding 
mean IE-1 and pp65-specific IFN-γ T-cell frequencies between 
patients with low CMV replication load and those with higher 
CMV replication requiring therapy (data not shown).
ROC curve analysis in basiliximab-treated patients con-
firmed 20 CMV (IE-1)–specific IFN-γ spots/3 × 105 PBMCs as 
an accurate cutoff discriminating patients at higher risk of CMV 
infection (area under the curve [AUC], 0.69 [95% CI, .56–.82]; 
P = .007). Conversely, pretransplant CMV (pp65)–specific IFN-γ 
Figure 3. Late-onset cytomegalovirus (CMV) infection rates between pretransplant high-risk and low-risk CMV (immediate-early protein 1)–specific cell-mediated immunity 
in all patients following prophylaxis therapy. Kaplan-Meier curves for late-onset CMV infection-free survival analysis (A) and late-onset CMV infection requiring antiviral 
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T-cell frequencies showed a poorer AUC predicting CMV in-
fection (AUC, 0.58 [95% CI, .44–.72]; P = .276) (Supplementary 
Figure 4A). The combination of both CMV-specific CMI did 
not outperform the prediction risk of CMV infection as com-
pared to CMV (IE-1)–specific CMI (Supplementary Figure 5).
Fifteen-Day Posttransplant CMV-Specific CMI and Risk of CMV 
Infection
At 15  days posttransplantation, a profound abrogation of 
both total T-lymphocyte counts and CMV-specific CMI was 
observed in all rATG-treated patients. Conversely, while 
basiliximab induction therapy did not affect posttransplant total 
T-lymphocytes counts, a significant, albeit less pronounced ab-
rogation of CMV-specific CMI was also found (Supplementary 
Figure 6A–C). The ROC analysis at this time point revealed 40 
CMV (IE-1)–specific IFN-γ spots/3 × 105 PBMCs as the most 
accurate cutoff predicting CMV infection (AUC, 0.80 [95% CI, 
.67–.94]; P < .001) (Supplementary Figure 4B).
Fifteen-day posttransplant CMV (IE-1)–specific CMI in 
basiliximab-treated patients outperformed the CMV infection 
prediction risk of pretransplant CMV-specific CMI (Table  2); 
indeed, high-risk CMI at 15  days after transplantation in pa-
tients on either preemptive or prophylaxis therapy predicted 
significantly higher risk of CMV infection, CMV infection re-
quiring treatment, and CMV disease as compared to low-risk 
CMI patients (Figures 4 and 5). Importantly, 32 of 75 (42.7%) 
pretransplant low-risk CMI patients on basiliximab became 
high-risk at 15 days, and 14 of 32 (43.8%) of them developed 
CMV infection. Furthermore, 12 of 15 (80%) of those following 
preemptive therapy developed CMV infection. Notably, none of 
the low-risk CMI patients developed late-onset CMV infection 
after prophylaxis therapy.
Figure 4. Cytomegalovirus (CMV) infection rates between 15-day posttransplant high-risk and low-risk CMV (immediate-early protein 1)–specific cell-mediated immunity in 
basiliximab-treated patients following preemptive therapy. Kaplan-Meier curves for CMV infection-free survival analysis (A), CMV infection requiring antiviral treatment-free 
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The combination of CMV-specific CMI against the 2 main 
CMV antigens (IE-1, pp65) did not improve the prediction 
risk of CMV (IE-1)–specific CMI (Supplementary Figure 7). 
Mean IE-1 and pp65-specific IFN-γ T-cell frequencies at 
15 days were numerically lower in patients with high CMV rep-
lication load than those with low CMV replication requiring 
therapy (25 ± 65.8 vs 70.3 ± 175 for IE-1 and 104.7 ± 99.7 vs 
185.8 ± 215.8 for pp65).
Protective Effect of the Type of Preventive Therapy According to 
CMV-Specific CMI
Compared to pretransplant CMV-specific CMI, 15-day 
posttransplant CMI risk stratification more accurately identi-
fied patients that might benefit from a universal prophylaxis 
vs a preemptive monitoring strategy for CMV prevention 
(Figure 6 and Supplementary Figures 8 and 9). Among low-risk 
CMI patients at 15 days on preemptive treatment, only 2 of 22 
(9%) developed CMV infection, 1 of 22 (4%) developed CMV 
infection requiring therapy, and none developed CMV disease.
DISCUSSION
Our study shows that the implementation of the T-SPOT.CMV 
assay in real-time clinical practice is feasible and safe. Our 
data demonstrate that CMV immune protection among D+/
R+ kidney transplantations is largely dependent on preformed 
CMV-specific CMI, and particularly against the IE-1 CMV an-
tigen, although this protective immune status is dramatically 
hampered by the use of T-cell depletion and in some patients 
by basiliximab induction therapy, which may abrogate pre-
formed CMV-specific CMI, thus increasing CMV infection 
risk. Notably, monitoring CMV-specific CMI at 15  days after 
transplantation outperformed the prediction accuracy of the 
test, as it captures the deleterious effect of induction therapy on 
preformed CMV-specific CMI.
The value of monitoring CMV-specific CMI to improve 
CMV risk stratification has been suggested by different studies, 
mainly focusing on D+/R– transplants or at later time points after 
transplantation [11, 15–23]. However, as R+ patients may have 
weak CMV-specific CMI despite detectable humoral immu-
nity [8, 9, 24, 25], we thus focused on the pretransplant setting 
as a clinically relevant timepoint for immune-risk stratifica-
tion. Indeed, up to 27.3% of R+ patients showed very low or no 
CMV-specific CMI at baseline. Importantly, these pretransplant 
high-risk patients showed significantly higher infection risk 
than low-risk CMI patients, regardless of induction therapy 
employed. However, the predictive capacity of the test signifi-
cantly improved when patients receiving rATG induction were 
excluded, as T-cell depletion can only affect those patients with 
preformed CMV-specific CMI [26]. We also found a functional 
abrogation of pretransplant CMV-specific CMI in some pa-
tients receiving basiliximab, which impacted their CMI against 
CMV. In fact, when the T-SPOT.CMV test was performed at 
15  days after transplantation, it improved its prediction risk; 
only 2 of 22 (9.1%) and no 15-day low-risk CMI patients re-
ceiving basiliximab and following a preemptive therapy devel-
oped CMV infection and disease, respectively, whereas up to 
26 of 32 (81.3%) and 7 of 32 (21.9%) did within the high-risk 
group. This is in line with findings in the hematopoietic stem 
cell transplant population wherein dynamic changes in CMV-
specific CMI between pretransplantation and 1  month better 
identified patients at risk of developing CMV infection [27].
The expansion capacity of recipient CMV-specific CMI, 
which ultimately entails a protective immune state against CMV 
infection, seems to be driven by D+ kidney allografts due to op-
timal donor viral peptide recognition by recipient T cells [9, 28]. 
Figure 5. Cytomegalovirus (CMV) infection rates between 15-day posttransplant high-risk and low-risk (immediate-early protein 1) CMV-specific cell-mediated immunity in 
basiliximab-treated patients following prophylaxis therapy. Kaplan-Meier curves for CMV infection-free survival analysis (A) and CMV infection requiring antiviral treatment-
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Interestingly, we found an association between poor HLA 
class I matching and higher CMV infection rates and, although 
not statistically different, patients with lower 15-day IE-1–spe-
cific CMI displayed numerically higher HLA class I mismatches 
than patients with higher IE-1-specific CMI, thus highlighting 
that CMV-specific CMI expansion may be more effective in pa-
tients with higher shared HLA class I antigens.
Moreover, the assessment of CMV-specific CMI against the 
pp65 antigen did not add any additional predictive value in our 
patients, underscoring a preponderance role of CMV (IE-1)–
specific CMI at the early phases of transplantation for CMV 
replication control [9, 10, 24]. Nevertheless, and as previously 
reported [29], few transplant recipients developing mild CMV 
replication showed weak CMI responses against pp65 antigens 
but moderate against IE-1, thus suggesting that the concomitant 
evaluation of CMV(pp65)–specific CMI may also be useful to 
refine CMV risk stratification.
A limitation of this study is the higher number of dropout 
rates in group B1 due to prophylaxis discontinuation and loss 
to follow-up. Nevertheless, a relevant number of CMV infec-
tions occurred within this group of patients and were therefore 
analyzed in the intention-to-treat analysis. Importantly, the re-
sults did not change the main outcome of the study and were 
in agreement with those observed in the per-protocol anal-
ysis. Despite only 86% of patients being evaluable at 15  days 
posttransplantation, the patients available for evaluation at this 
timepoint were well-balanced among the study subgroups.
In conclusion, our study shows that monitoring CMV-
specific CMI, particularly at early timepoints after transplanta-
tion, accurately predicts the risk of developing CMV infection 
Figure 6. Cytomegalovirus (CMV) infection rates between CMV preventive strategies in basiliximab-treated patients classified as low-risk or high-risk cell-mediated im-
munity (CMI) according to the pretransplant or 15-day CMI test. Kaplan-Meier curves for CMV infection-free survival analysis among pretransplant low-risk CMI patients (A), 
pretransplant high-risk CMI patients (B), 15-day posttransplant low-risk CMI patients (C), and 15-day posttransplant high-risk CMI patients (D). Abbreviations: CI, confidence 
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in patients not receiving T-cell induction therapy. D+/R+ kidney 
recipients receiving basiliximab with high-risk CMV-specific 
CMI should preferentially follow a close systematic follow-up 
or receive antiviral prophylaxis, whereas low-risk CMI pa-
tients may require a less stringent preventive approach. The 
results of this study provide an opportunity for implementing 
personalized medicine to manage CMV infection in kidney 
transplantation.
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